Inhibitors of SARS-Coronavirus-2 infection

Bidragets beskrivning

Pharmaceutical interventions to decrease COVID-19 severity and lethality are urgently needed globally. Our multidisciplinary consortium is focused to develop therapies for COVID-19 at University of Helsinki and VTT using different approaches: by cloning and producing human antibodies cloned from individual immune cells from the patients recovered from COVID-19 disease, and by screening safe-in-human compounds for SARS-CoV-2 inhibitory effects in in vitro systems. Structural studies will produce information of SARS-CoV-2 binding at the molecular level, informing also further engineering of the binding antibodies. Animal models of SARS-CoV-2 infection will be developed for further in vivo testing of the inhibitors.
Visa mer

Startår

2020

Slutår

2022

Beviljade finansiering






Olli Kallioniemi Orcid -palvelun logo
220 792 €

Rollen i Finlands Akademis konsortium

Partner

Övriga parter i konsortiet

Partner
Helsingfors universitet (336494)
192 617 €
Partner
Teknologiska forskningscentralen VTT Ab (336495)
219 256 €
Partner
Helsingfors universitet (336492)
238 620 €
Partner
Helsingfors universitet (336493)
189 926 €
Leader
Helsingfors universitet (336490)
499 937 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt med särskild inriktning

Övriga uppgifter

Finansieringsbeslutets nummer

336496

Vetenskapsområden

Växtbiologi, mikrobiologi, virologi

Forskningsområden

Mikrobiologia

Temaområden

Lisätalousarvio III 2020

Identifierade teman

covid, pandemic, vaccines